BlackRock Inc. - RECURSION PHARMACEUTICALS IN ownership

RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 158 filers reported holding RECURSION PHARMACEUTICALS IN in Q1 2023. The put-call ratio across all filers is 0.85 and the average weighting 0.9%.

Quarter-by-quarter ownership
BlackRock Inc. ownership history of RECURSION PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$90,705,698
+4.5%
11,856,954
+2.0%
0.00%
+50.0%
Q2 2023$86,797,118
+22.4%
11,619,427
+9.3%
0.00%0.0%
Q1 2023$70,914,487
-13.8%
10,631,857
-0.3%
0.00%
-33.3%
Q4 2022$82,247,381
-20.9%
10,667,624
+9.2%
0.00%
-25.0%
Q3 2022$103,921,000
+54.9%
9,767,040
+18.5%
0.00%
+100.0%
Q2 2022$67,087,000
+39.7%
8,241,782
+22.9%
0.00%
+100.0%
Q1 2022$48,029,000
-58.5%
6,707,757
-0.8%
0.00%
-66.7%
Q4 2021$115,846,000
+184.8%
6,762,684
+282.6%
0.00%
+200.0%
Q3 2021$40,673,000
-22.8%
1,767,664
+22.4%
0.00%0.0%
Q2 2021$52,709,0001,444,0780.00%
Other shareholders
RECURSION PHARMACEUTICALS IN shareholders Q1 2023
NameSharesValueWeighting ↓
Kinnevik AB (publ) 10,405,668$77,730,340100.00%
Data Collective IV GP, LLC 5,941,120$44,380,16632.86%
MV Management XI, L.L.C. 1,971,908$14,730,15325.77%
MIC Capital Management UK LLP 8,451,758$63,134,63512.84%
Yong Rong (HK) Asset Management Ltd 1,174,200$8,7723.85%
ArchPoint Investors 1,114,626$8,326,2563.22%
PLATINUM INVESTMENT MANAGEMENT LTD 2,711,148$20,252,2760.70%
HARVARD MANAGEMENT CO INC 882,129$6,5900.65%
Diametric Capital, LP 119,906$895,6980.40%
Lingotto Investment Management LLP 775,077$5,789,8250.37%
View complete list of RECURSION PHARMACEUTICALS IN shareholders